AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The RAS/MAPK signaling pathway is crucial in cancer development and is often dysregulated by BRAF or RAS mutations.
• Single-agent inhibitors of this pathway show limited efficacy in KRAS-mutant tumors, unlike in BRAF-mutant melanoma.
• Combined inhibition of pathway nodes like MEK1/2 and ERK1/2 may be required for effective treatment of KRAS-mutant cancers.

Purpose of the Study:

• To discover and characterize AZD0364, a novel ERK1/2 inhibitor.
• To evaluate the efficacy of AZD0364, alone and in combination with selumetinib, in preclinical cancer models.
• To explore the potential of combined MEK1/2 and ERK1/2 inhibition as a therapeutic strategy for KRAS-mutant tumors.

Main Methods:

• Discovery and biochemical characterization of AZD0364, an ATP-competitive ERK1/2 inhibitor.
• In vitro studies assessing AZD0364's effect on biomarkers and proliferation in BRAF- and KRAS-mutant cell lines.
• In vivo xenograft studies evaluating AZD0364 and selumetinib combination efficacy and pathway modulation in KRAS-mutant models.

Main Results:

• AZD0364 demonstrated potent and selective ERK1/2 inhibition, reducing proliferation in sensitive cell lines.
• AZD0364 monotherapy achieved tumor regression in BRAF- and KRAS-mutant xenografts.
• The combination of AZD0364 and selumetinib enhanced efficacy in KRAS-mutant models, leading to deeper and more durable pathway suppression and significant tumor regressions.

Conclusions:

• AZD0364 is a potent ERK1/2 inhibitor with anti-tumor activity.
• Combined MEK1/2 and ERK1/2 inhibition, using AZD0364 and selumetinib, is a promising strategy for targeting KRAS-mutant tumors.
• This combination therapy offers a potential clinical approach for overcoming resistance to single-agent therapies in KRAS-mutant cancers.